Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aytu BioPharma Inc (Ayut BioPharma) is a specialty pharmaceutical company that offers prescription therapeutics and consumer health products. Its key prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. The company markets ADHD products under Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT brands. It also markets ZolpiMist, a short-term treatment for insomnia characterized by difficulties with sleep initiation, Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine suspension to treat numerous allergic conditions, and Tri-Vi-Flor and Poly-Vi-Flor, two complementary fluoride-based prescription vitamin products for infants and children with fluoride deficiency. The company offers its prescription therapeutics through third parties and consumer health products are sold directly to consumers. Aytu BioPharma is headquartered in Denver, Colorado, the US.
Headquarters
United States of America
Address
7900 E. Union Avenue, Suite 920, Denver, Colorado, 80237
Website
aytubio.com
Telephone
1 720 4376580
No of Employees
150
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AYTU (NASD)
Revenue (2022)
$107.4M
11.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
84.3%
(2022 vs 2021)
Market Cap*
$16.8M
Net Profit Margin (2022)
XYZ
85.9%
(2022 vs 2021)
* As of and is in US$
Aytu BioPharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Adzenys XR-ODT |
| Cotempla XR-ODT |
| Karbinal ER |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Stock Listings/IPO | In June, the company announced to raise US$4.0 million funds in IPO of shares. |
| 2021 | Acquisitions/Mergers/Takeovers | In March, the company closes merger with Neos Therapeutics. |
| 2020 | Contracts/Agreements | In December, the company entered into a merger agreement with Neos Therapeutics, Inc. |
Competitor Comparison
| Key Parameters | Aytu BioPharma Inc | Abiomed Inc | Osmotica Pharmaceutical Corp | Adlon Therapeutics LP | Ironshore Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Denver | Danvers | Marietta | - | Durham |
| State/Province | Colorado | Massachusetts | Georgia | - | North Carolina |
| No. of Employees | 150 | 2,003 | 414 | - | 39 |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joshua R Disbrow | Chief Executive Officer; Chairman | Executive Board | 2015 | 48 |
| Mark Oki | Treasurer; Chief Financial Officer; Secretary | Senior Management | 2022 | 54 |
| Topher Brooke | Chief Operating Officer | Senior Management | 2021 | - |
| Jarrett T Disbrow | Chief Business Officer | Senior Management | 2015 | - |
| Greg Pyszczymuka | Chief Commercial Officer | Senior Management | - | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer